- Coordinator
- Servicio Madrileno De Salud, Spain
- Runs
- 1 January 2026 to 31 December 2029
- Status
- Running
- EU funding
- €6.2m
- Total cost
- €6.2m
- Partners
- 21 organisations in 9 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101190620
What the project is doing
In the project's own words, from its summary on CORDIS.
Early ARV treatment in sub-Saharan Africa (SSA) reaches only approximately 50% of infants born with HIV. Mortality in infants in the first 12 months after diagnosis is still over 10% in early treated infants diagnosed at birth, 25% in infants diagnosed with opportunistic infections. According to our experience, the probability of virological control 1 year after diagnosis is only 25 to 35%, even after the rollout of dolutegravir (DTG).
As a solution for this problem, we propose the addition of four shots of subcutaneous (SC), long-half-life broadly neutralizing antibodies (bNAbs) at diagnosis, and 3, 6 and 9 months after diagnosis, as an add-on to standard oral ART will provide immediate therapeutic benefit and decrease HIV viral load levels in the most critical period of life of children with HIV, allowing for a decreased risk of co-infections, HIV-encephalopathy and death.
We will evaluate for the first time the efficacy of combining two bNAbs (ePGT121v1-LS and VRC07-523-LS, as intensification therapy for ART, to achieve viral suppression within one year after diagnosis in high risk-infants with HIV. The specific aims to achieve this general aim will be: to perform a phase II/III trial with bNAbs, capacity strengthening related with bNAbs in Africa, to characterize biomarkers for anticipating response to bNAbs, to identify the barriers and facilitators of rollout of bNAbs as a treatment, and to liaise with relevant stakeholdersThe pathway to achieve this aim will be a collaborative framework between a scientific network with partners in several SSA countries, producers of bNAbs, and European and African laboratories.
With this approach, the probability of viral suppression 1 year after diagnosis will be increased from 30% to 95% to achieve 2030 UNAIDS 3rd target. This achievement will impact in a reduction of HIV- associated morbidity and mortality in the first year of life and beyond in more than 130 000 infants every year.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Servicio Madrileno De Salud | Madrid | Spain | Coordinator |
| Centre Pasteur Cameroon | Yaounde | CM | Participant |
| Fundacion Para La Investigacion Biomedica Del Hospital Universitario 12 De Octubre | Madrid | Spain | Third party |
| Fundacion Para La Investigacion E Innovacion Biomedica Del Hu Infanta Sofia Y Del Henares | Madrid | Spain | Third party |
| Fundacion Privada Instituto De Salud Global Barcelona | Barcelona | Spain | Participant |
| Institut National De La Sante Et De La Recherche Medicale | Paris | France | Participant |
| Fondazione Penta Ets | Padova | Italy | Participant |
| Universita Degli Studi Di Roma Tor Vergata | Roma | Italy | Participant |
| Iavi Africa Limited | Nairobi | Kenya | Participant |
| Fundacao Ariel Glaser Contra O Sida Pediatrico | Maputo | MZ | Participant |
| Fundacao Manhica | Vila Da Manhica Maputo | MZ | Participant |
| Universidade Eduardo Mondlane | Maputo | MZ | Participant |
| Stichting International Aids Vaccine Initiative the Netherlands | Amsterdam | Netherlands | Third party |
| Stichting Radboud Universitair Medisch Centrum | Nijmegen | Netherlands | Participant |
| International Aids Vaccine Initiative Inc | New York | United States | Associatedpartner |
| The Regents of the University of California | Oakland | United States | Associatedpartner |
| Africa Health Research Institute (ahri) | Durban | South Africa | Participant |
| Enhancing Care Foundation Npc | Durban | South Africa | Participant |
| Stellenbosch University | Stellenbosch | South Africa | Participant |
| Umkhuseli Innovation and Research Management NPC | Pietermaritzburg | South Africa | Participant |
| Wits Health Consortium (pty) Ltd | Johannesburg | South Africa | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI